nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—Protein Kinase Inhibitors—Vemurafenib—skin cancer	0.413	0.58	CiPCiCtD
Bosutinib—P-Glycoprotein Inhibitors—Vemurafenib—skin cancer	0.298	0.42	CiPCiCtD
Bosutinib—EGFR—Docetaxel—skin cancer	0.0312	0.489	CbGbCtD
Bosutinib—ABCB1—Vismodegib—skin cancer	0.00685	0.107	CbGbCtD
Bosutinib—CYP3A4—Imiquimod—skin cancer	0.00592	0.0928	CbGbCtD
Bosutinib—CYP3A4—Temozolomide—skin cancer	0.00592	0.0928	CbGbCtD
Bosutinib—CYP3A4—Vismodegib—skin cancer	0.00411	0.0643	CbGbCtD
Bosutinib—ABCB1—Dactinomycin—skin cancer	0.0036	0.0564	CbGbCtD
Bosutinib—CYP3A4—Vemurafenib—skin cancer	0.00325	0.0508	CbGbCtD
Bosutinib—ABCB1—Docetaxel—skin cancer	0.00186	0.0291	CbGbCtD
Bosutinib—CYP3A4—Docetaxel—skin cancer	0.00111	0.0174	CbGbCtD
Bosutinib—WEE1—Paclitaxel—Docetaxel—skin cancer	0.00091	0.484	CbGdCrCtD
Bosutinib—CDK2—Paclitaxel—Docetaxel—skin cancer	0.000741	0.395	CbGdCrCtD
Bosutinib—CHEK2—Paclitaxel—Docetaxel—skin cancer	0.000227	0.121	CbGdCrCtD
Bosutinib—Pneumonia—Bleomycin—skin cancer	0.000173	0.00273	CcSEcCtD
Bosutinib—Pancytopenia—Dactinomycin—skin cancer	0.000171	0.00269	CcSEcCtD
Bosutinib—Malaise—Imiquimod—skin cancer	0.00017	0.00269	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.000169	0.00267	CcSEcCtD
Bosutinib—Neutropenia—Dactinomycin—skin cancer	0.000168	0.00265	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Temozolomide—skin cancer	0.000166	0.00262	CcSEcCtD
Bosutinib—Cough—Imiquimod—skin cancer	0.000165	0.0026	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000165	0.0026	CcSEcCtD
Bosutinib—Fluid retention—Docetaxel—skin cancer	0.000163	0.00258	CcSEcCtD
Bosutinib—Pneumonia—Dactinomycin—skin cancer	0.000161	0.00254	CcSEcCtD
Bosutinib—Chest pain—Imiquimod—skin cancer	0.000161	0.00254	CcSEcCtD
Bosutinib—Arthralgia—Imiquimod—skin cancer	0.000161	0.00254	CcSEcCtD
Bosutinib—Myalgia—Imiquimod—skin cancer	0.000161	0.00254	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00016	0.00252	CcSEcCtD
Bosutinib—Discomfort—Imiquimod—skin cancer	0.000159	0.00251	CcSEcCtD
Bosutinib—Decreased appetite—Vemurafenib—skin cancer	0.000157	0.00248	CcSEcCtD
Bosutinib—Bronchitis—Temozolomide—skin cancer	0.000156	0.00247	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000156	0.00246	CcSEcCtD
Bosutinib—Fatigue—Vemurafenib—skin cancer	0.000156	0.00246	CcSEcCtD
Bosutinib—Nasopharyngitis—Fluorouracil—skin cancer	0.000155	0.00245	CcSEcCtD
Bosutinib—Pancytopenia—Temozolomide—skin cancer	0.000154	0.00244	CcSEcCtD
Bosutinib—Oedema—Imiquimod—skin cancer	0.000154	0.00243	CcSEcCtD
Bosutinib—Infection—Imiquimod—skin cancer	0.000153	0.00242	CcSEcCtD
Bosutinib—Neutropenia—Temozolomide—skin cancer	0.000152	0.0024	CcSEcCtD
Bosutinib—Nervous system disorder—Imiquimod—skin cancer	0.000151	0.00239	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Temozolomide—skin cancer	0.000151	0.00238	CcSEcCtD
Bosutinib—Skin disorder—Imiquimod—skin cancer	0.00015	0.00236	CcSEcCtD
Bosutinib—Agranulocytosis—Dactinomycin—skin cancer	0.000149	0.00236	CcSEcCtD
Bosutinib—Pneumonia—Temozolomide—skin cancer	0.000146	0.0023	CcSEcCtD
Bosutinib—Infestation NOS—Temozolomide—skin cancer	0.000145	0.00229	CcSEcCtD
Bosutinib—Infestation—Temozolomide—skin cancer	0.000145	0.00229	CcSEcCtD
Bosutinib—Hepatitis—Dactinomycin—skin cancer	0.000144	0.00227	CcSEcCtD
Bosutinib—Body temperature increased—Vemurafenib—skin cancer	0.000143	0.00226	CcSEcCtD
Bosutinib—Pancytopenia—Fluorouracil—skin cancer	0.000142	0.00224	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00014	0.00222	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Fluorouracil—skin cancer	0.000139	0.0022	CcSEcCtD
Bosutinib—Dyspnoea—Imiquimod—skin cancer	0.000137	0.00217	CcSEcCtD
Bosutinib—Hepatobiliary disease—Temozolomide—skin cancer	0.000137	0.00216	CcSEcCtD
Bosutinib—Erythema multiforme—Dactinomycin—skin cancer	0.000136	0.00215	CcSEcCtD
Bosutinib—Pneumonia—Fluorouracil—skin cancer	0.000134	0.00212	CcSEcCtD
Bosutinib—Decreased appetite—Imiquimod—skin cancer	0.000134	0.00212	CcSEcCtD
Bosutinib—Infestation—Fluorouracil—skin cancer	0.000133	0.00211	CcSEcCtD
Bosutinib—Infestation NOS—Fluorouracil—skin cancer	0.000133	0.00211	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Imiquimod—skin cancer	0.000133	0.0021	CcSEcCtD
Bosutinib—Fatigue—Imiquimod—skin cancer	0.000133	0.0021	CcSEcCtD
Bosutinib—Pain—Imiquimod—skin cancer	0.000132	0.00208	CcSEcCtD
Bosutinib—Renal impairment—Docetaxel—skin cancer	0.000131	0.00207	CcSEcCtD
Bosutinib—Hepatitis—Temozolomide—skin cancer	0.00013	0.00205	CcSEcCtD
Bosutinib—Asthenia—Vemurafenib—skin cancer	0.00013	0.00205	CcSEcCtD
Bosutinib—Urinary tract disorder—Temozolomide—skin cancer	0.000128	0.00203	CcSEcCtD
Bosutinib—Oedema peripheral—Temozolomide—skin cancer	0.000128	0.00202	CcSEcCtD
Bosutinib—Pruritus—Vemurafenib—skin cancer	0.000128	0.00202	CcSEcCtD
Bosutinib—Connective tissue disorder—Temozolomide—skin cancer	0.000128	0.00202	CcSEcCtD
Bosutinib—Urethral disorder—Temozolomide—skin cancer	0.000127	0.00201	CcSEcCtD
Bosutinib—Feeling abnormal—Imiquimod—skin cancer	0.000127	0.00201	CcSEcCtD
Bosutinib—Gastrointestinal pain—Imiquimod—skin cancer	0.000126	0.00199	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000125	0.00197	CcSEcCtD
Bosutinib—Agranulocytosis—Fluorouracil—skin cancer	0.000125	0.00197	CcSEcCtD
Bosutinib—Ill-defined disorder—Bleomycin—skin cancer	0.000124	0.00197	CcSEcCtD
Bosutinib—Anaemia—Bleomycin—skin cancer	0.000124	0.00196	CcSEcCtD
Bosutinib—Diarrhoea—Vemurafenib—skin cancer	0.000124	0.00195	CcSEcCtD
Bosutinib—Erythema multiforme—Temozolomide—skin cancer	0.000123	0.00194	CcSEcCtD
Bosutinib—Urticaria—Imiquimod—skin cancer	0.000122	0.00193	CcSEcCtD
Bosutinib—CAMK1D—head—skin cancer	0.000122	0.00172	CbGeAlD
Bosutinib—Abdominal pain—Imiquimod—skin cancer	0.000122	0.00192	CcSEcCtD
Bosutinib—Body temperature increased—Imiquimod—skin cancer	0.000122	0.00192	CcSEcCtD
Bosutinib—TLK1—lymph node—skin cancer	0.000122	0.00172	CbGeAlD
Bosutinib—AXL—skin of body—skin cancer	0.000121	0.00172	CbGeAlD
Bosutinib—PDGFRB—neck—skin cancer	0.000121	0.00172	CbGeAlD
Bosutinib—Tinnitus—Temozolomide—skin cancer	0.000121	0.00191	CcSEcCtD
Bosutinib—EPHA4—mammalian vulva—skin cancer	0.000121	0.00171	CbGeAlD
Bosutinib—Malaise—Bleomycin—skin cancer	0.000121	0.00191	CcSEcCtD
Bosutinib—Cardiac disorder—Temozolomide—skin cancer	0.000121	0.00191	CcSEcCtD
Bosutinib—MAP2K1—lymphoid tissue—skin cancer	0.000121	0.00171	CbGeAlD
Bosutinib—STK24—head—skin cancer	0.000121	0.0017	CbGeAlD
Bosutinib—MAP4K4—female reproductive system—skin cancer	0.00012	0.0017	CbGeAlD
Bosutinib—Leukopenia—Bleomycin—skin cancer	0.00012	0.0019	CcSEcCtD
Bosutinib—PRKCQ—lymph node—skin cancer	0.00012	0.0017	CbGeAlD
Bosutinib—CSK—lymphoid tissue—skin cancer	0.00012	0.00169	CbGeAlD
Bosutinib—EPHA2—epithelium—skin cancer	0.00012	0.00169	CbGeAlD
Bosutinib—MAP2K2—mammalian vulva—skin cancer	0.00012	0.00169	CbGeAlD
Bosutinib—ULK3—mammalian vulva—skin cancer	0.00012	0.00169	CbGeAlD
Bosutinib—BCR—female reproductive system—skin cancer	0.00012	0.00169	CbGeAlD
Bosutinib—Dizziness—Vemurafenib—skin cancer	0.00012	0.00189	CcSEcCtD
Bosutinib—CSNK1A1—lymphoid tissue—skin cancer	0.000119	0.00168	CbGeAlD
Bosutinib—MAP3K12—female reproductive system—skin cancer	0.000119	0.00168	CbGeAlD
Bosutinib—CLK1—lymphoid tissue—skin cancer	0.000118	0.00167	CbGeAlD
Bosutinib—HCK—lymphoid tissue—skin cancer	0.000118	0.00167	CbGeAlD
Bosutinib—MAP3K7—mammalian vulva—skin cancer	0.000118	0.00166	CbGeAlD
Bosutinib—Immune system disorder—Temozolomide—skin cancer	0.000117	0.00185	CcSEcCtD
Bosutinib—Mediastinal disorder—Temozolomide—skin cancer	0.000117	0.00185	CcSEcCtD
Bosutinib—Cough—Bleomycin—skin cancer	0.000117	0.00185	CcSEcCtD
Bosutinib—FER—head—skin cancer	0.000117	0.00165	CbGeAlD
Bosutinib—EPHA5—head—skin cancer	0.000117	0.00165	CbGeAlD
Bosutinib—ALK—head—skin cancer	0.000117	0.00165	CbGeAlD
Bosutinib—TYRO3—head—skin cancer	0.000117	0.00165	CbGeAlD
Bosutinib—MAP2K1—female reproductive system—skin cancer	0.000116	0.00164	CbGeAlD
Bosutinib—STK35—female reproductive system—skin cancer	0.000116	0.00164	CbGeAlD
Bosutinib—TBK1—mammalian vulva—skin cancer	0.000116	0.00164	CbGeAlD
Bosutinib—Dehydration—Docetaxel—skin cancer	0.000116	0.00184	CcSEcCtD
Bosutinib—Ill-defined disorder—Dactinomycin—skin cancer	0.000116	0.00183	CcSEcCtD
Bosutinib—LYN—head—skin cancer	0.000116	0.00164	CbGeAlD
Bosutinib—Anaemia—Dactinomycin—skin cancer	0.000116	0.00183	CcSEcCtD
Bosutinib—CSK—female reproductive system—skin cancer	0.000116	0.00163	CbGeAlD
Bosutinib—Vomiting—Vemurafenib—skin cancer	0.000115	0.00181	CcSEcCtD
Bosutinib—CSNK1A1—female reproductive system—skin cancer	0.000115	0.00162	CbGeAlD
Bosutinib—MAP3K19—head—skin cancer	0.000114	0.00162	CbGeAlD
Bosutinib—Myalgia—Bleomycin—skin cancer	0.000114	0.0018	CcSEcCtD
Bosutinib—Chest pain—Bleomycin—skin cancer	0.000114	0.0018	CcSEcCtD
Bosutinib—Abdominal pain upper—Docetaxel—skin cancer	0.000114	0.0018	CcSEcCtD
Bosutinib—CLK1—female reproductive system—skin cancer	0.000114	0.00161	CbGeAlD
Bosutinib—IRAK1—mammalian vulva—skin cancer	0.000114	0.00161	CbGeAlD
Bosutinib—Rash—Vemurafenib—skin cancer	0.000114	0.0018	CcSEcCtD
Bosutinib—Dermatitis—Vemurafenib—skin cancer	0.000114	0.0018	CcSEcCtD
Bosutinib—FYN—skin of body—skin cancer	0.000114	0.00161	CbGeAlD
Bosutinib—YES1—connective tissue—skin cancer	0.000114	0.00161	CbGeAlD
Bosutinib—Headache—Vemurafenib—skin cancer	0.000113	0.00179	CcSEcCtD
Bosutinib—Malnutrition—Temozolomide—skin cancer	0.000113	0.00179	CcSEcCtD
Bosutinib—Discomfort—Bleomycin—skin cancer	0.000113	0.00178	CcSEcCtD
Bosutinib—Malaise—Dactinomycin—skin cancer	0.000113	0.00178	CcSEcCtD
Bosutinib—DSTYK—lymph node—skin cancer	0.000113	0.00159	CbGeAlD
Bosutinib—BMX—lymph node—skin cancer	0.000113	0.00159	CbGeAlD
Bosutinib—CLK3—lymph node—skin cancer	0.000113	0.00159	CbGeAlD
Bosutinib—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000113	0.00178	CcSEcCtD
Bosutinib—PTK2B—lymphoid tissue—skin cancer	0.000112	0.00159	CbGeAlD
Bosutinib—TAOK3—connective tissue—skin cancer	0.000112	0.00159	CbGeAlD
Bosutinib—TNK2—head—skin cancer	0.000112	0.00158	CbGeAlD
Bosutinib—Leukopenia—Dactinomycin—skin cancer	0.000112	0.00177	CcSEcCtD
Bosutinib—CAMK2G—female reproductive system—skin cancer	0.000112	0.00158	CbGeAlD
Bosutinib—BMP2K—female reproductive system—skin cancer	0.000112	0.00158	CbGeAlD
Bosutinib—RPS6KB1—mammalian vulva—skin cancer	0.000112	0.00158	CbGeAlD
Bosutinib—Nasopharyngitis—Docetaxel—skin cancer	0.000112	0.00176	CcSEcCtD
Bosutinib—BLK—lymph node—skin cancer	0.000111	0.00158	CbGeAlD
Bosutinib—LCK—mammalian vulva—skin cancer	0.000111	0.00157	CbGeAlD
Bosutinib—FGR—mammalian vulva—skin cancer	0.000111	0.00157	CbGeAlD
Bosutinib—MAP3K3—skin of body—skin cancer	0.000111	0.00157	CbGeAlD
Bosutinib—LRRK2—female reproductive system—skin cancer	0.000111	0.00157	CbGeAlD
Bosutinib—Dysgeusia—Temozolomide—skin cancer	0.000111	0.00175	CcSEcCtD
Bosutinib—AXL—mammalian vulva—skin cancer	0.000111	0.00157	CbGeAlD
Bosutinib—Asthenia—Imiquimod—skin cancer	0.000111	0.00175	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Docetaxel—skin cancer	0.00011	0.00174	CcSEcCtD
Bosutinib—PHKG1—lymph node—skin cancer	0.00011	0.00156	CbGeAlD
Bosutinib—CASK—lymph node—skin cancer	0.00011	0.00156	CbGeAlD
Bosutinib—Oedema—Bleomycin—skin cancer	0.00011	0.00173	CcSEcCtD
Bosutinib—Anaphylactic shock—Bleomycin—skin cancer	0.00011	0.00173	CcSEcCtD
Bosutinib—Back pain—Temozolomide—skin cancer	0.000109	0.00173	CcSEcCtD
Bosutinib—ABL1—nipple—skin cancer	0.000109	0.00155	CbGeAlD
Bosutinib—SRC—connective tissue—skin cancer	0.000109	0.00154	CbGeAlD
Bosutinib—Pruritus—Imiquimod—skin cancer	0.000109	0.00172	CcSEcCtD
Bosutinib—STK3—head—skin cancer	0.000109	0.00154	CbGeAlD
Bosutinib—ERBB4—head—skin cancer	0.000109	0.00154	CbGeAlD
Bosutinib—EIF2AK1—lymph node—skin cancer	0.000109	0.00154	CbGeAlD
Bosutinib—Infection—Bleomycin—skin cancer	0.000109	0.00172	CcSEcCtD
Bosutinib—SIK1—lymphoid tissue—skin cancer	0.000109	0.00154	CbGeAlD
Bosutinib—IRAK4—lymphoid tissue—skin cancer	0.000109	0.00154	CbGeAlD
Bosutinib—PTK2B—female reproductive system—skin cancer	0.000108	0.00153	CbGeAlD
Bosutinib—ROCK1—head—skin cancer	0.000108	0.00152	CbGeAlD
Bosutinib—Nausea—Vemurafenib—skin cancer	0.000107	0.0017	CcSEcCtD
Bosutinib—Thrombocytopenia—Bleomycin—skin cancer	0.000107	0.00169	CcSEcCtD
Bosutinib—TXK—lymph node—skin cancer	0.000107	0.00151	CbGeAlD
Bosutinib—SLK—mammalian vulva—skin cancer	0.000107	0.00151	CbGeAlD
Bosutinib—Myalgia—Dactinomycin—skin cancer	0.000107	0.00168	CcSEcCtD
Bosutinib—ERBB3—lymphoid tissue—skin cancer	0.000106	0.0015	CbGeAlD
Bosutinib—CSNK1E—female reproductive system—skin cancer	0.000106	0.0015	CbGeAlD
Bosutinib—MAP2K2—lymphoid tissue—skin cancer	0.000106	0.0015	CbGeAlD
Bosutinib—EPHB4—mammalian vulva—skin cancer	0.000106	0.0015	CbGeAlD
Bosutinib—VRK2—lymph node—skin cancer	0.000106	0.00149	CbGeAlD
Bosutinib—FES—lymph node—skin cancer	0.000106	0.00149	CbGeAlD
Bosutinib—Diarrhoea—Imiquimod—skin cancer	0.000105	0.00167	CcSEcCtD
Bosutinib—MAP3K2—lymphoid tissue—skin cancer	0.000105	0.00149	CbGeAlD
Bosutinib—Discomfort—Dactinomycin—skin cancer	0.000105	0.00166	CcSEcCtD
Bosutinib—Ill-defined disorder—Temozolomide—skin cancer	0.000105	0.00166	CcSEcCtD
Bosutinib—SIK1—female reproductive system—skin cancer	0.000105	0.00148	CbGeAlD
Bosutinib—Anaemia—Temozolomide—skin cancer	0.000105	0.00165	CcSEcCtD
Bosutinib—BMPR2—head—skin cancer	0.000105	0.00148	CbGeAlD
Bosutinib—EPHA2—mammalian vulva—skin cancer	0.000104	0.00147	CbGeAlD
Bosutinib—SRC—epithelium—skin cancer	0.000104	0.00147	CbGeAlD
Bosutinib—STK36—head—skin cancer	0.000104	0.00147	CbGeAlD
Bosutinib—EPHB3—head—skin cancer	0.000104	0.00147	CbGeAlD
Bosutinib—EPHA4—female reproductive system—skin cancer	0.000104	0.00147	CbGeAlD
Bosutinib—FYN—mammalian vulva—skin cancer	0.000104	0.00147	CbGeAlD
Bosutinib—TNIK—lymph node—skin cancer	0.000104	0.00146	CbGeAlD
Bosutinib—SYK—lymph node—skin cancer	0.000104	0.00146	CbGeAlD
Bosutinib—PTK2—lymphoid tissue—skin cancer	0.000103	0.00146	CbGeAlD
Bosutinib—TBK1—lymphoid tissue—skin cancer	0.000103	0.00146	CbGeAlD
Bosutinib—ERBB3—female reproductive system—skin cancer	0.000103	0.00145	CbGeAlD
Bosutinib—Pancytopenia—Docetaxel—skin cancer	0.000103	0.00162	CcSEcCtD
Bosutinib—CDK2—lymph node—skin cancer	0.000103	0.00145	CbGeAlD
Bosutinib—MERTK—head—skin cancer	0.000103	0.00145	CbGeAlD
Bosutinib—MAP2K2—female reproductive system—skin cancer	0.000102	0.00145	CbGeAlD
Bosutinib—ULK3—female reproductive system—skin cancer	0.000102	0.00145	CbGeAlD
Bosutinib—Oedema—Dactinomycin—skin cancer	0.000102	0.00161	CcSEcCtD
Bosutinib—Malaise—Temozolomide—skin cancer	0.000102	0.00161	CcSEcCtD
Bosutinib—Dizziness—Imiquimod—skin cancer	0.000102	0.00161	CcSEcCtD
Bosutinib—MAP3K2—female reproductive system—skin cancer	0.000102	0.00144	CbGeAlD
Bosutinib—STK26—lymph node—skin cancer	0.000102	0.00144	CbGeAlD
Bosutinib—Infection—Dactinomycin—skin cancer	0.000101	0.0016	CcSEcCtD
Bosutinib—Leukopenia—Temozolomide—skin cancer	0.000101	0.0016	CcSEcCtD
Bosutinib—MAP3K3—mammalian vulva—skin cancer	0.000101	0.00143	CbGeAlD
Bosutinib—MAP4K5—mammalian vulva—skin cancer	0.000101	0.00143	CbGeAlD
Bosutinib—Neutropenia—Docetaxel—skin cancer	0.000101	0.0016	CcSEcCtD
Bosutinib—MAP4K4—head—skin cancer	0.000101	0.00142	CbGeAlD
Bosutinib—Thrombocytopenia—Dactinomycin—skin cancer	0.0001	0.00158	CcSEcCtD
Bosutinib—BCR—head—skin cancer	9.99e-05	0.00141	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Bleomycin—skin cancer	9.98e-05	0.00158	CcSEcCtD
Bosutinib—PTK2—female reproductive system—skin cancer	9.96e-05	0.00141	CbGeAlD
Bosutinib—TBK1—female reproductive system—skin cancer	9.96e-05	0.00141	CbGeAlD
Bosutinib—RPS6KB1—lymphoid tissue—skin cancer	9.93e-05	0.0014	CbGeAlD
Bosutinib—MAP3K12—head—skin cancer	9.92e-05	0.0014	CbGeAlD
Bosutinib—Cough—Temozolomide—skin cancer	9.88e-05	0.00156	CcSEcCtD
Bosutinib—FGR—lymphoid tissue—skin cancer	9.87e-05	0.0014	CbGeAlD
Bosutinib—SRC—skin of body—skin cancer	9.87e-05	0.0014	CbGeAlD
Bosutinib—AXL—lymphoid tissue—skin cancer	9.83e-05	0.00139	CbGeAlD
Bosutinib—CHEK2—lymph node—skin cancer	9.82e-05	0.00139	CbGeAlD
Bosutinib—CSF1R—connective tissue—skin cancer	9.81e-05	0.00139	CbGeAlD
Bosutinib—Vomiting—Imiquimod—skin cancer	9.8e-05	0.00155	CcSEcCtD
Bosutinib—Dyspnoea—Bleomycin—skin cancer	9.76e-05	0.00154	CcSEcCtD
Bosutinib—IRAK1—female reproductive system—skin cancer	9.76e-05	0.00138	CbGeAlD
Bosutinib—WEE1—lymph node—skin cancer	9.74e-05	0.00138	CbGeAlD
Bosutinib—DMPK—lymph node—skin cancer	9.74e-05	0.00138	CbGeAlD
Bosutinib—Rash—Imiquimod—skin cancer	9.72e-05	0.00153	CcSEcCtD
Bosutinib—MAP2K1—head—skin cancer	9.72e-05	0.00137	CbGeAlD
Bosutinib—STK35—head—skin cancer	9.72e-05	0.00137	CbGeAlD
Bosutinib—Dermatitis—Imiquimod—skin cancer	9.71e-05	0.00153	CcSEcCtD
Bosutinib—Pneumonia—Docetaxel—skin cancer	9.69e-05	0.00153	CcSEcCtD
Bosutinib—Headache—Imiquimod—skin cancer	9.66e-05	0.00152	CcSEcCtD
Bosutinib—CSK—head—skin cancer	9.65e-05	0.00137	CbGeAlD
Bosutinib—Anaemia—Fluorouracil—skin cancer	9.64e-05	0.00152	CcSEcCtD
Bosutinib—Myalgia—Temozolomide—skin cancer	9.64e-05	0.00152	CcSEcCtD
Bosutinib—Arthralgia—Temozolomide—skin cancer	9.64e-05	0.00152	CcSEcCtD
Bosutinib—Infestation NOS—Docetaxel—skin cancer	9.63e-05	0.00152	CcSEcCtD
Bosutinib—Infestation—Docetaxel—skin cancer	9.63e-05	0.00152	CcSEcCtD
Bosutinib—CSNK1A1—head—skin cancer	9.59e-05	0.00136	CbGeAlD
Bosutinib—RPS6KB1—female reproductive system—skin cancer	9.58e-05	0.00135	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	9.57e-05	0.00151	CcSEcCtD
Bosutinib—CLK1—head—skin cancer	9.53e-05	0.00135	CbGeAlD
Bosutinib—HCK—head—skin cancer	9.53e-05	0.00135	CbGeAlD
Bosutinib—Discomfort—Temozolomide—skin cancer	9.52e-05	0.0015	CcSEcCtD
Bosutinib—FGR—female reproductive system—skin cancer	9.52e-05	0.00135	CbGeAlD
Bosutinib—Decreased appetite—Bleomycin—skin cancer	9.52e-05	0.0015	CcSEcCtD
Bosutinib—AXL—female reproductive system—skin cancer	9.48e-05	0.00134	CbGeAlD
Bosutinib—Renal failure—Docetaxel—skin cancer	9.47e-05	0.0015	CcSEcCtD
Bosutinib—Pain—Bleomycin—skin cancer	9.36e-05	0.00148	CcSEcCtD
Bosutinib—CAMK2G—head—skin cancer	9.35e-05	0.00132	CbGeAlD
Bosutinib—BMP2K—head—skin cancer	9.35e-05	0.00132	CbGeAlD
Bosutinib—YES1—mammalian vulva—skin cancer	9.35e-05	0.00132	CbGeAlD
Bosutinib—Leukopenia—Fluorouracil—skin cancer	9.33e-05	0.00147	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Dactinomycin—skin cancer	9.3e-05	0.00147	CcSEcCtD
Bosutinib—STK25—lymph node—skin cancer	9.3e-05	0.00131	CbGeAlD
Bosutinib—LRRK2—head—skin cancer	9.27e-05	0.00131	CbGeAlD
Bosutinib—STK10—mammalian vulva—skin cancer	9.27e-05	0.00131	CbGeAlD
Bosutinib—Anaphylactic shock—Temozolomide—skin cancer	9.24e-05	0.00146	CcSEcCtD
Bosutinib—Oedema—Temozolomide—skin cancer	9.24e-05	0.00146	CcSEcCtD
Bosutinib—TAOK3—mammalian vulva—skin cancer	9.23e-05	0.00131	CbGeAlD
Bosutinib—EPHA3—lymph node—skin cancer	9.23e-05	0.00131	CbGeAlD
Bosutinib—EPHA2—lymphoid tissue—skin cancer	9.22e-05	0.0013	CbGeAlD
Bosutinib—FYN—lymphoid tissue—skin cancer	9.2e-05	0.0013	CbGeAlD
Bosutinib—Infection—Temozolomide—skin cancer	9.18e-05	0.00145	CcSEcCtD
Bosutinib—Nausea—Imiquimod—skin cancer	9.16e-05	0.00145	CcSEcCtD
Bosutinib—Hepatobiliary disease—Docetaxel—skin cancer	9.11e-05	0.00144	CcSEcCtD
Bosutinib—EPHB4—female reproductive system—skin cancer	9.06e-05	0.00128	CbGeAlD
Bosutinib—Nervous system disorder—Temozolomide—skin cancer	9.06e-05	0.00143	CcSEcCtD
Bosutinib—Thrombocytopenia—Temozolomide—skin cancer	9.04e-05	0.00143	CcSEcCtD
Bosutinib—PLK2—lymph node—skin cancer	9.04e-05	0.00128	CbGeAlD
Bosutinib—PTK2B—head—skin cancer	9.03e-05	0.00128	CbGeAlD
Bosutinib—Feeling abnormal—Bleomycin—skin cancer	9.02e-05	0.00142	CcSEcCtD
Bosutinib—MAP4K5—lymphoid tissue—skin cancer	8.99e-05	0.00127	CbGeAlD
Bosutinib—Agranulocytosis—Docetaxel—skin cancer	8.99e-05	0.00142	CcSEcCtD
Bosutinib—SIK3—lymph node—skin cancer	8.98e-05	0.00127	CbGeAlD
Bosutinib—Skin disorder—Temozolomide—skin cancer	8.97e-05	0.00142	CcSEcCtD
Bosutinib—EPHA2—female reproductive system—skin cancer	8.89e-05	0.00126	CbGeAlD
Bosutinib—CSNK1E—head—skin cancer	8.89e-05	0.00126	CbGeAlD
Bosutinib—Chest pain—Fluorouracil—skin cancer	8.88e-05	0.0014	CcSEcCtD
Bosutinib—Myalgia—Fluorouracil—skin cancer	8.88e-05	0.0014	CcSEcCtD
Bosutinib—Decreased appetite—Dactinomycin—skin cancer	8.88e-05	0.0014	CcSEcCtD
Bosutinib—FYN—female reproductive system—skin cancer	8.87e-05	0.00125	CbGeAlD
Bosutinib—CSF1R—skin of body—skin cancer	8.86e-05	0.00125	CbGeAlD
Bosutinib—Fatigue—Dactinomycin—skin cancer	8.81e-05	0.00139	CcSEcCtD
Bosutinib—Discomfort—Fluorouracil—skin cancer	8.77e-05	0.00139	CcSEcCtD
Bosutinib—SIK1—head—skin cancer	8.75e-05	0.00124	CbGeAlD
Bosutinib—IRAK4—head—skin cancer	8.75e-05	0.00124	CbGeAlD
Bosutinib—Pain—Dactinomycin—skin cancer	8.73e-05	0.00138	CcSEcCtD
Bosutinib—Urticaria—Bleomycin—skin cancer	8.7e-05	0.00137	CcSEcCtD
Bosutinib—PDGFRB—connective tissue—skin cancer	8.7e-05	0.00123	CbGeAlD
Bosutinib—MAP4K5—female reproductive system—skin cancer	8.67e-05	0.00123	CbGeAlD
Bosutinib—MAP3K3—female reproductive system—skin cancer	8.67e-05	0.00123	CbGeAlD
Bosutinib—EPHA4—head—skin cancer	8.66e-05	0.00122	CbGeAlD
Bosutinib—Body temperature increased—Bleomycin—skin cancer	8.66e-05	0.00137	CcSEcCtD
Bosutinib—Hepatitis—Docetaxel—skin cancer	8.65e-05	0.00137	CcSEcCtD
Bosutinib—STK4—lymph node—skin cancer	8.64e-05	0.00122	CbGeAlD
Bosutinib—ERBB3—head—skin cancer	8.58e-05	0.00121	CbGeAlD
Bosutinib—ULK3—head—skin cancer	8.56e-05	0.00121	CbGeAlD
Bosutinib—MAP2K2—head—skin cancer	8.56e-05	0.00121	CbGeAlD
Bosutinib—CAMK1D—lymph node—skin cancer	8.54e-05	0.00121	CbGeAlD
Bosutinib—Urinary tract disorder—Docetaxel—skin cancer	8.54e-05	0.00135	CcSEcCtD
Bosutinib—Oedema peripheral—Docetaxel—skin cancer	8.52e-05	0.00135	CcSEcCtD
Bosutinib—Oedema—Fluorouracil—skin cancer	8.51e-05	0.00134	CcSEcCtD
Bosutinib—Anaphylactic shock—Fluorouracil—skin cancer	8.51e-05	0.00134	CcSEcCtD
Bosutinib—Connective tissue disorder—Docetaxel—skin cancer	8.5e-05	0.00134	CcSEcCtD
Bosutinib—MAP3K2—head—skin cancer	8.49e-05	0.0012	CbGeAlD
Bosutinib—Urethral disorder—Docetaxel—skin cancer	8.48e-05	0.00134	CcSEcCtD
Bosutinib—Infection—Fluorouracil—skin cancer	8.46e-05	0.00134	CcSEcCtD
Bosutinib—STK24—lymph node—skin cancer	8.44e-05	0.00119	CbGeAlD
Bosutinib—Feeling abnormal—Dactinomycin—skin cancer	8.42e-05	0.00133	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Temozolomide—skin cancer	8.42e-05	0.00133	CcSEcCtD
Bosutinib—Gastrointestinal pain—Dactinomycin—skin cancer	8.35e-05	0.00132	CcSEcCtD
Bosutinib—Nervous system disorder—Fluorouracil—skin cancer	8.35e-05	0.00132	CcSEcCtD
Bosutinib—Thrombocytopenia—Fluorouracil—skin cancer	8.33e-05	0.00132	CcSEcCtD
Bosutinib—PTK2—head—skin cancer	8.32e-05	0.00118	CbGeAlD
Bosutinib—TBK1—head—skin cancer	8.32e-05	0.00118	CbGeAlD
Bosutinib—YES1—lymphoid tissue—skin cancer	8.3e-05	0.00117	CbGeAlD
Bosutinib—MAP2K5—mammalian vulva—skin cancer	8.28e-05	0.00117	CbGeAlD
Bosutinib—PDGFRB—epithelium—skin cancer	8.26e-05	0.00117	CbGeAlD
Bosutinib—Dyspnoea—Temozolomide—skin cancer	8.24e-05	0.0013	CcSEcCtD
Bosutinib—STK10—lymphoid tissue—skin cancer	8.23e-05	0.00116	CbGeAlD
Bosutinib—TAOK3—lymphoid tissue—skin cancer	8.2e-05	0.00116	CbGeAlD
Bosutinib—Erythema multiforme—Docetaxel—skin cancer	8.18e-05	0.00129	CcSEcCtD
Bosutinib—FER—lymph node—skin cancer	8.17e-05	0.00116	CbGeAlD
Bosutinib—ALK—lymph node—skin cancer	8.17e-05	0.00116	CbGeAlD
Bosutinib—CSF1R—mammalian vulva—skin cancer	8.08e-05	0.00114	CbGeAlD
Bosutinib—Body temperature increased—Dactinomycin—skin cancer	8.07e-05	0.00127	CcSEcCtD
Bosutinib—Abdominal pain—Dactinomycin—skin cancer	8.07e-05	0.00127	CcSEcCtD
Bosutinib—Decreased appetite—Temozolomide—skin cancer	8.03e-05	0.00127	CcSEcCtD
Bosutinib—Cardiac disorder—Docetaxel—skin cancer	8.02e-05	0.00127	CcSEcCtD
Bosutinib—YES1—female reproductive system—skin cancer	8.01e-05	0.00113	CbGeAlD
Bosutinib—MAP4K1—lymph node—skin cancer	8e-05	0.00113	CbGeAlD
Bosutinib—RPS6KB1—head—skin cancer	8e-05	0.00113	CbGeAlD
Bosutinib—SRC—lymphoid tissue—skin cancer	7.99e-05	0.00113	CbGeAlD
Bosutinib—Gastrointestinal disorder—Temozolomide—skin cancer	7.97e-05	0.00126	CcSEcCtD
Bosutinib—Fatigue—Temozolomide—skin cancer	7.96e-05	0.00126	CcSEcCtD
Bosutinib—BTK—lymph node—skin cancer	7.96e-05	0.00113	CbGeAlD
Bosutinib—FGR—head—skin cancer	7.95e-05	0.00112	CbGeAlD
Bosutinib—STK10—female reproductive system—skin cancer	7.94e-05	0.00112	CbGeAlD
Bosutinib—AXL—head—skin cancer	7.92e-05	0.00112	CbGeAlD
Bosutinib—TAOK3—female reproductive system—skin cancer	7.91e-05	0.00112	CbGeAlD
Bosutinib—Pain—Temozolomide—skin cancer	7.9e-05	0.00125	CcSEcCtD
Bosutinib—Asthenia—Bleomycin—skin cancer	7.86e-05	0.00124	CcSEcCtD
Bosutinib—PDGFRB—skin of body—skin cancer	7.86e-05	0.00111	CbGeAlD
Bosutinib—TNK2—lymph node—skin cancer	7.85e-05	0.00111	CbGeAlD
Bosutinib—Immune system disorder—Docetaxel—skin cancer	7.81e-05	0.00123	CcSEcCtD
Bosutinib—Mediastinal disorder—Docetaxel—skin cancer	7.79e-05	0.00123	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Fluorouracil—skin cancer	7.75e-05	0.00122	CcSEcCtD
Bosutinib—ABL1—connective tissue—skin cancer	7.75e-05	0.0011	CbGeAlD
Bosutinib—Pruritus—Bleomycin—skin cancer	7.75e-05	0.00122	CcSEcCtD
Bosutinib—MAP4K2—lymph node—skin cancer	7.74e-05	0.00109	CbGeAlD
Bosutinib—SRC—female reproductive system—skin cancer	7.71e-05	0.00109	CbGeAlD
Bosutinib—STK3—lymph node—skin cancer	7.63e-05	0.00108	CbGeAlD
Bosutinib—Feeling abnormal—Temozolomide—skin cancer	7.61e-05	0.0012	CcSEcCtD
Bosutinib—Dyspnoea—Fluorouracil—skin cancer	7.59e-05	0.0012	CcSEcCtD
Bosutinib—Gastrointestinal pain—Temozolomide—skin cancer	7.55e-05	0.00119	CcSEcCtD
Bosutinib—Malnutrition—Docetaxel—skin cancer	7.53e-05	0.00119	CcSEcCtD
Bosutinib—EPHA2—head—skin cancer	7.43e-05	0.00105	CbGeAlD
Bosutinib—FYN—head—skin cancer	7.41e-05	0.00105	CbGeAlD
Bosutinib—Decreased appetite—Fluorouracil—skin cancer	7.4e-05	0.00117	CcSEcCtD
Bosutinib—Dysgeusia—Docetaxel—skin cancer	7.37e-05	0.00116	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Fluorouracil—skin cancer	7.35e-05	0.00116	CcSEcCtD
Bosutinib—Urticaria—Temozolomide—skin cancer	7.34e-05	0.00116	CcSEcCtD
Bosutinib—Asthenia—Dactinomycin—skin cancer	7.33e-05	0.00116	CcSEcCtD
Bosutinib—BMPR2—lymph node—skin cancer	7.32e-05	0.00103	CbGeAlD
Bosutinib—Abdominal pain—Temozolomide—skin cancer	7.3e-05	0.00115	CcSEcCtD
Bosutinib—Body temperature increased—Temozolomide—skin cancer	7.3e-05	0.00115	CcSEcCtD
Bosutinib—Back pain—Docetaxel—skin cancer	7.28e-05	0.00115	CcSEcCtD
Bosutinib—Pain—Fluorouracil—skin cancer	7.28e-05	0.00115	CcSEcCtD
Bosutinib—EPHB3—lymph node—skin cancer	7.26e-05	0.00103	CbGeAlD
Bosutinib—STK36—lymph node—skin cancer	7.26e-05	0.00103	CbGeAlD
Bosutinib—MAP3K3—head—skin cancer	7.25e-05	0.00102	CbGeAlD
Bosutinib—MAP4K5—head—skin cancer	7.25e-05	0.00102	CbGeAlD
Bosutinib—MERTK—lymph node—skin cancer	7.18e-05	0.00101	CbGeAlD
Bosutinib—CSF1R—lymphoid tissue—skin cancer	7.17e-05	0.00101	CbGeAlD
Bosutinib—PDGFRB—mammalian vulva—skin cancer	7.16e-05	0.00101	CbGeAlD
Bosutinib—MAP2K5—female reproductive system—skin cancer	7.09e-05	0.001	CbGeAlD
Bosutinib—MAP4K4—lymph node—skin cancer	7.05e-05	0.000996	CbGeAlD
Bosutinib—Feeling abnormal—Fluorouracil—skin cancer	7.01e-05	0.00111	CcSEcCtD
Bosutinib—ABL1—skin of body—skin cancer	7e-05	0.00099	CbGeAlD
Bosutinib—NUAK2—lymph node—skin cancer	6.99e-05	0.000989	CbGeAlD
Bosutinib—BCR—lymph node—skin cancer	6.99e-05	0.000989	CbGeAlD
Bosutinib—Diarrhoea—Dactinomycin—skin cancer	6.99e-05	0.0011	CcSEcCtD
Bosutinib—Vomiting—Bleomycin—skin cancer	6.96e-05	0.0011	CcSEcCtD
Bosutinib—Anaemia—Docetaxel—skin cancer	6.96e-05	0.0011	CcSEcCtD
Bosutinib—MAP3K12—lymph node—skin cancer	6.95e-05	0.000982	CbGeAlD
Bosutinib—CSF1R—female reproductive system—skin cancer	6.92e-05	0.000978	CbGeAlD
Bosutinib—Rash—Bleomycin—skin cancer	6.9e-05	0.00109	CcSEcCtD
Bosutinib—Dermatitis—Bleomycin—skin cancer	6.9e-05	0.00109	CcSEcCtD
Bosutinib—MAP2K1—lymph node—skin cancer	6.8e-05	0.000962	CbGeAlD
Bosutinib—STK35—lymph node—skin cancer	6.8e-05	0.000962	CbGeAlD
Bosutinib—Urticaria—Fluorouracil—skin cancer	6.76e-05	0.00107	CcSEcCtD
Bosutinib—CSK—lymph node—skin cancer	6.76e-05	0.000956	CbGeAlD
Bosutinib—Leukopenia—Docetaxel—skin cancer	6.74e-05	0.00106	CcSEcCtD
Bosutinib—Body temperature increased—Fluorouracil—skin cancer	6.73e-05	0.00106	CcSEcCtD
Bosutinib—CSNK1A1—lymph node—skin cancer	6.72e-05	0.00095	CbGeAlD
Bosutinib—YES1—head—skin cancer	6.69e-05	0.000946	CbGeAlD
Bosutinib—HCK—lymph node—skin cancer	6.67e-05	0.000944	CbGeAlD
Bosutinib—CLK1—lymph node—skin cancer	6.67e-05	0.000944	CbGeAlD
Bosutinib—ABL2—lymph node—skin cancer	6.63e-05	0.000938	CbGeAlD
Bosutinib—STK10—head—skin cancer	6.63e-05	0.000938	CbGeAlD
Bosutinib—Asthenia—Temozolomide—skin cancer	6.63e-05	0.00105	CcSEcCtD
Bosutinib—TAOK3—head—skin cancer	6.61e-05	0.000934	CbGeAlD
Bosutinib—Cough—Docetaxel—skin cancer	6.57e-05	0.00104	CcSEcCtD
Bosutinib—BMP2K—lymph node—skin cancer	6.55e-05	0.000926	CbGeAlD
Bosutinib—CAMK2G—lymph node—skin cancer	6.55e-05	0.000926	CbGeAlD
Bosutinib—Pruritus—Temozolomide—skin cancer	6.54e-05	0.00103	CcSEcCtD
Bosutinib—Nausea—Bleomycin—skin cancer	6.5e-05	0.00103	CcSEcCtD
Bosutinib—Vomiting—Dactinomycin—skin cancer	6.49e-05	0.00103	CcSEcCtD
Bosutinib—LRRK2—lymph node—skin cancer	6.49e-05	0.000918	CbGeAlD
Bosutinib—EGFR—lymph node—skin cancer	6.47e-05	0.000915	CbGeAlD
Bosutinib—Rash—Dactinomycin—skin cancer	6.44e-05	0.00102	CcSEcCtD
Bosutinib—SRC—head—skin cancer	6.44e-05	0.00091	CbGeAlD
Bosutinib—Chest pain—Docetaxel—skin cancer	6.41e-05	0.00101	CcSEcCtD
Bosutinib—Arthralgia—Docetaxel—skin cancer	6.41e-05	0.00101	CcSEcCtD
Bosutinib—Myalgia—Docetaxel—skin cancer	6.41e-05	0.00101	CcSEcCtD
Bosutinib—ABL1—mammalian vulva—skin cancer	6.39e-05	0.000903	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	6.36e-05	0.001	CcSEcCtD
Bosutinib—PDGFRB—lymphoid tissue—skin cancer	6.36e-05	0.000899	CbGeAlD
Bosutinib—PTK2B—lymph node—skin cancer	6.33e-05	0.000894	CbGeAlD
Bosutinib—Diarrhoea—Temozolomide—skin cancer	6.32e-05	0.000998	CcSEcCtD
Bosutinib—CSNK1E—lymph node—skin cancer	6.22e-05	0.00088	CbGeAlD
Bosutinib—Oedema—Docetaxel—skin cancer	6.14e-05	0.00097	CcSEcCtD
Bosutinib—Anaphylactic shock—Docetaxel—skin cancer	6.14e-05	0.00097	CcSEcCtD
Bosutinib—PDGFRB—female reproductive system—skin cancer	6.13e-05	0.000867	CbGeAlD
Bosutinib—SIK1—lymph node—skin cancer	6.13e-05	0.000866	CbGeAlD
Bosutinib—IRAK4—lymph node—skin cancer	6.13e-05	0.000866	CbGeAlD
Bosutinib—Dizziness—Temozolomide—skin cancer	6.11e-05	0.000965	CcSEcCtD
Bosutinib—Infection—Docetaxel—skin cancer	6.1e-05	0.000964	CcSEcCtD
Bosutinib—Nausea—Dactinomycin—skin cancer	6.07e-05	0.000958	CcSEcCtD
Bosutinib—EPHA4—lymph node—skin cancer	6.06e-05	0.000858	CbGeAlD
Bosutinib—Nervous system disorder—Docetaxel—skin cancer	6.02e-05	0.000951	CcSEcCtD
Bosutinib—Pruritus—Fluorouracil—skin cancer	6.02e-05	0.000951	CcSEcCtD
Bosutinib—Thrombocytopenia—Docetaxel—skin cancer	6.01e-05	0.00095	CcSEcCtD
Bosutinib—ERBB3—lymph node—skin cancer	6.01e-05	0.000849	CbGeAlD
Bosutinib—MAP2K2—lymph node—skin cancer	5.99e-05	0.000847	CbGeAlD
Bosutinib—ULK3—lymph node—skin cancer	5.99e-05	0.000847	CbGeAlD
Bosutinib—Skin disorder—Docetaxel—skin cancer	5.97e-05	0.000942	CcSEcCtD
Bosutinib—MAP3K2—lymph node—skin cancer	5.95e-05	0.000841	CbGeAlD
Bosutinib—MAP2K5—head—skin cancer	5.92e-05	0.000837	CbGeAlD
Bosutinib—MAP3K7—lymph node—skin cancer	5.89e-05	0.000833	CbGeAlD
Bosutinib—Vomiting—Temozolomide—skin cancer	5.87e-05	0.000927	CcSEcCtD
Bosutinib—TBK1—lymph node—skin cancer	5.82e-05	0.000824	CbGeAlD
Bosutinib—PTK2—lymph node—skin cancer	5.82e-05	0.000824	CbGeAlD
Bosutinib—Rash—Temozolomide—skin cancer	5.82e-05	0.00092	CcSEcCtD
Bosutinib—Diarrhoea—Fluorouracil—skin cancer	5.82e-05	0.00092	CcSEcCtD
Bosutinib—Dermatitis—Temozolomide—skin cancer	5.82e-05	0.000919	CcSEcCtD
Bosutinib—Headache—Temozolomide—skin cancer	5.79e-05	0.000914	CcSEcCtD
Bosutinib—CSF1R—head—skin cancer	5.78e-05	0.000817	CbGeAlD
Bosutinib—IRAK1—lymph node—skin cancer	5.71e-05	0.000807	CbGeAlD
Bosutinib—ABL1—lymphoid tissue—skin cancer	5.67e-05	0.000802	CbGeAlD
Bosutinib—Dizziness—Fluorouracil—skin cancer	5.63e-05	0.000889	CcSEcCtD
Bosutinib—RPS6KB1—lymph node—skin cancer	5.6e-05	0.000792	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Docetaxel—skin cancer	5.6e-05	0.000884	CcSEcCtD
Bosutinib—LCK—lymph node—skin cancer	5.57e-05	0.000788	CbGeAlD
Bosutinib—FGR—lymph node—skin cancer	5.57e-05	0.000788	CbGeAlD
Bosutinib—AXL—lymph node—skin cancer	5.55e-05	0.000784	CbGeAlD
Bosutinib—Nausea—Temozolomide—skin cancer	5.49e-05	0.000866	CcSEcCtD
Bosutinib—Dyspnoea—Docetaxel—skin cancer	5.48e-05	0.000865	CcSEcCtD
Bosutinib—ABL1—female reproductive system—skin cancer	5.47e-05	0.000773	CbGeAlD
Bosutinib—Vomiting—Fluorouracil—skin cancer	5.41e-05	0.000855	CcSEcCtD
Bosutinib—Rash—Fluorouracil—skin cancer	5.37e-05	0.000847	CcSEcCtD
Bosutinib—Dermatitis—Fluorouracil—skin cancer	5.36e-05	0.000847	CcSEcCtD
Bosutinib—Decreased appetite—Docetaxel—skin cancer	5.34e-05	0.000843	CcSEcCtD
Bosutinib—SLK—lymph node—skin cancer	5.34e-05	0.000755	CbGeAlD
Bosutinib—Headache—Fluorouracil—skin cancer	5.33e-05	0.000842	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Docetaxel—skin cancer	5.3e-05	0.000837	CcSEcCtD
Bosutinib—EPHB4—lymph node—skin cancer	5.3e-05	0.00075	CbGeAlD
Bosutinib—Fatigue—Docetaxel—skin cancer	5.3e-05	0.000836	CcSEcCtD
Bosutinib—Pain—Docetaxel—skin cancer	5.25e-05	0.00083	CcSEcCtD
Bosutinib—EPHA2—lymph node—skin cancer	5.2e-05	0.000735	CbGeAlD
Bosutinib—FYN—lymph node—skin cancer	5.19e-05	0.000734	CbGeAlD
Bosutinib—PDGFRB—head—skin cancer	5.13e-05	0.000725	CbGeAlD
Bosutinib—MAP4K5—lymph node—skin cancer	5.07e-05	0.000717	CbGeAlD
Bosutinib—MAP3K3—lymph node—skin cancer	5.07e-05	0.000717	CbGeAlD
Bosutinib—Feeling abnormal—Docetaxel—skin cancer	5.06e-05	0.000799	CcSEcCtD
Bosutinib—Nausea—Fluorouracil—skin cancer	5.06e-05	0.000798	CcSEcCtD
Bosutinib—Gastrointestinal pain—Docetaxel—skin cancer	5.02e-05	0.000793	CcSEcCtD
Bosutinib—Body temperature increased—Docetaxel—skin cancer	4.86e-05	0.000767	CcSEcCtD
Bosutinib—Abdominal pain—Docetaxel—skin cancer	4.86e-05	0.000767	CcSEcCtD
Bosutinib—ABCB1—blood vessel—skin cancer	4.7e-05	0.000665	CbGeAlD
Bosutinib—YES1—lymph node—skin cancer	4.69e-05	0.000663	CbGeAlD
Bosutinib—STK10—lymph node—skin cancer	4.64e-05	0.000657	CbGeAlD
Bosutinib—TAOK3—lymph node—skin cancer	4.63e-05	0.000654	CbGeAlD
Bosutinib—ABL1—head—skin cancer	4.57e-05	0.000646	CbGeAlD
Bosutinib—SRC—lymph node—skin cancer	4.51e-05	0.000637	CbGeAlD
Bosutinib—Asthenia—Docetaxel—skin cancer	4.41e-05	0.000696	CcSEcCtD
Bosutinib—Pruritus—Docetaxel—skin cancer	4.35e-05	0.000686	CcSEcCtD
Bosutinib—Diarrhoea—Docetaxel—skin cancer	4.2e-05	0.000664	CcSEcCtD
Bosutinib—MAP2K5—lymph node—skin cancer	4.15e-05	0.000586	CbGeAlD
Bosutinib—Dizziness—Docetaxel—skin cancer	4.06e-05	0.000641	CcSEcCtD
Bosutinib—CSF1R—lymph node—skin cancer	4.05e-05	0.000572	CbGeAlD
Bosutinib—Vomiting—Docetaxel—skin cancer	3.91e-05	0.000617	CcSEcCtD
Bosutinib—Rash—Docetaxel—skin cancer	3.87e-05	0.000612	CcSEcCtD
Bosutinib—Dermatitis—Docetaxel—skin cancer	3.87e-05	0.000611	CcSEcCtD
Bosutinib—Headache—Docetaxel—skin cancer	3.85e-05	0.000608	CcSEcCtD
Bosutinib—Nausea—Docetaxel—skin cancer	3.65e-05	0.000576	CcSEcCtD
Bosutinib—PDGFRB—lymph node—skin cancer	3.59e-05	0.000507	CbGeAlD
Bosutinib—ABL1—lymph node—skin cancer	3.2e-05	0.000452	CbGeAlD
Bosutinib—CYP3A4—female reproductive system—skin cancer	2.4e-05	0.00034	CbGeAlD
Bosutinib—ABCB1—epithelium—skin cancer	2.29e-05	0.000324	CbGeAlD
Bosutinib—ABCB1—mammalian vulva—skin cancer	1.99e-05	0.000281	CbGeAlD
Bosutinib—ABCB1—lymphoid tissue—skin cancer	1.76e-05	0.000249	CbGeAlD
Bosutinib—ABCB1—female reproductive system—skin cancer	1.7e-05	0.00024	CbGeAlD
Bosutinib—ABCB1—head—skin cancer	1.42e-05	0.000201	CbGeAlD
Bosutinib—ABCB1—lymph node—skin cancer	9.95e-06	0.000141	CbGeAlD
Bosutinib—MAP3K7—Immune System—NRAS—skin cancer	1.45e-06	1.62e-05	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—IL6—skin cancer	1.45e-06	1.62e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—NRAS—skin cancer	1.45e-06	1.62e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—HRAS—skin cancer	1.45e-06	1.62e-05	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—IL6—skin cancer	1.45e-06	1.62e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—TP53—skin cancer	1.45e-06	1.62e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—KRAS—skin cancer	1.44e-06	1.61e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—IL6—skin cancer	1.44e-06	1.61e-05	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—HRAS—skin cancer	1.44e-06	1.61e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—TP53—skin cancer	1.43e-06	1.61e-05	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—IL6—skin cancer	1.43e-06	1.6e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—IL6—skin cancer	1.42e-06	1.6e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—HRAS—skin cancer	1.42e-06	1.59e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—HRAS—skin cancer	1.42e-06	1.59e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—HRAS—skin cancer	1.42e-06	1.59e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—KRAS—skin cancer	1.42e-06	1.59e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—PTGS2—skin cancer	1.41e-06	1.58e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—IL6—skin cancer	1.41e-06	1.58e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—IL6—skin cancer	1.41e-06	1.58e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—KRAS—skin cancer	1.41e-06	1.58e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PTGS2—skin cancer	1.41e-06	1.58e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—IL6—skin cancer	1.4e-06	1.57e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—KRAS—skin cancer	1.4e-06	1.56e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—NRAS—skin cancer	1.39e-06	1.55e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—IL6—skin cancer	1.39e-06	1.55e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—HRAS—skin cancer	1.38e-06	1.55e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—HRAS—skin cancer	1.37e-06	1.54e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—IL6—skin cancer	1.36e-06	1.52e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—IL6—skin cancer	1.36e-06	1.52e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—NRAS—skin cancer	1.36e-06	1.52e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—IL6—skin cancer	1.36e-06	1.52e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—HRAS—skin cancer	1.35e-06	1.52e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—KRAS—skin cancer	1.35e-06	1.51e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CSPG4—skin cancer	1.34e-06	1.51e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TERT—skin cancer	1.34e-06	1.5e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—NRAS—skin cancer	1.34e-06	1.5e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—KRAS—skin cancer	1.33e-06	1.48e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—IL6—skin cancer	1.31e-06	1.47e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—BRAF—skin cancer	1.3e-06	1.46e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—KRAS—skin cancer	1.3e-06	1.45e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—NRAS—skin cancer	1.3e-06	1.45e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—IL6—skin cancer	1.29e-06	1.45e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—HRAS—skin cancer	1.29e-06	1.45e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—BRAF—skin cancer	1.29e-06	1.45e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TERT—skin cancer	1.29e-06	1.44e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—NRAS—skin cancer	1.29e-06	1.44e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TP53—skin cancer	1.28e-06	1.44e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—BRAF—skin cancer	1.27e-06	1.42e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—NRAS—skin cancer	1.27e-06	1.42e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—HRAS—skin cancer	1.25e-06	1.4e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—HRAS—skin cancer	1.25e-06	1.4e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—KRAS—skin cancer	1.25e-06	1.4e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—KRAS—skin cancer	1.25e-06	1.4e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—HRAS—skin cancer	1.25e-06	1.4e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—BRAF—skin cancer	1.25e-06	1.39e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—HRAS—skin cancer	1.24e-06	1.39e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—NRAS—skin cancer	1.24e-06	1.39e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—NRAS—skin cancer	1.24e-06	1.39e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—IL6—skin cancer	1.24e-06	1.39e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—NRAS—skin cancer	1.24e-06	1.38e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—BRAF—skin cancer	1.23e-06	1.37e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—HRAS—skin cancer	1.23e-06	1.37e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—PTGS2—skin cancer	1.22e-06	1.37e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—BRAF—skin cancer	1.22e-06	1.37e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—NRAS—skin cancer	1.21e-06	1.36e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—NRAS—skin cancer	1.2e-06	1.35e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—HRAS—skin cancer	1.2e-06	1.35e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TP53—skin cancer	1.2e-06	1.34e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—HRAS—skin cancer	1.2e-06	1.34e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—NRAS—skin cancer	1.2e-06	1.34e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—IL6—skin cancer	1.2e-06	1.34e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—IL6—skin cancer	1.2e-06	1.34e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—KRAS—skin cancer	1.19e-06	1.34e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—IL6—skin cancer	1.19e-06	1.34e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—NRAS—skin cancer	1.19e-06	1.33e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—HRAS—skin cancer	1.19e-06	1.33e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—NRAS—skin cancer	1.19e-06	1.33e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—PTGS2—skin cancer	1.18e-06	1.32e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—NRAS—skin cancer	1.17e-06	1.31e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—KRAS—skin cancer	1.17e-06	1.31e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL6—skin cancer	1.15e-06	1.29e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—KRAS—skin cancer	1.15e-06	1.29e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—HRAS—skin cancer	1.15e-06	1.29e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—NRAS—skin cancer	1.14e-06	1.28e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TERT—skin cancer	1.14e-06	1.28e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL6—skin cancer	1.14e-06	1.27e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—NRAS—skin cancer	1.13e-06	1.26e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—HRAS—skin cancer	1.13e-06	1.26e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—KRAS—skin cancer	1.12e-06	1.25e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—KRAS—skin cancer	1.11e-06	1.24e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—HRAS—skin cancer	1.1e-06	1.24e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—NRAS—skin cancer	1.1e-06	1.23e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—IL6—skin cancer	1.1e-06	1.23e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—NRAS—skin cancer	1.09e-06	1.23e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—KRAS—skin cancer	1.09e-06	1.22e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL6—skin cancer	1.08e-06	1.21e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—KRAS—skin cancer	1.07e-06	1.2e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—KRAS—skin cancer	1.07e-06	1.2e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—NRAS—skin cancer	1.06e-06	1.19e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—KRAS—skin cancer	1.06e-06	1.19e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—HRAS—skin cancer	1.06e-06	1.19e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—HRAS—skin cancer	1.06e-06	1.19e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—BRAF—skin cancer	1.06e-06	1.19e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—IL6—skin cancer	1.06e-06	1.18e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—NRAS—skin cancer	1.05e-06	1.18e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—PTGS2—skin cancer	1.04e-06	1.17e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—KRAS—skin cancer	1.04e-06	1.17e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—skin cancer	1.04e-06	1.16e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—KRAS—skin cancer	1.04e-06	1.16e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—NRAS—skin cancer	1.03e-06	1.15e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—KRAS—skin cancer	1.03e-06	1.15e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—KRAS—skin cancer	1.03e-06	1.15e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—skin cancer	1.02e-06	1.15e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—BRAF—skin cancer	1.02e-06	1.14e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—KRAS—skin cancer	1.02e-06	1.14e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL6—skin cancer	1.02e-06	1.14e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—HRAS—skin cancer	1.01e-06	1.14e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—KRAS—skin cancer	1.01e-06	1.13e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—NRAS—skin cancer	9.95e-07	1.11e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—HRAS—skin cancer	9.92e-07	1.11e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—NRAS—skin cancer	9.92e-07	1.11e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—skin cancer	9.85e-07	1.1e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—KRAS—skin cancer	9.82e-07	1.1e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—HRAS—skin cancer	9.78e-07	1.1e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL6—skin cancer	9.71e-07	1.09e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—KRAS—skin cancer	9.7e-07	1.09e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—NRAS—skin cancer	9.5e-07	1.06e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL6—skin cancer	9.5e-07	1.06e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—HRAS—skin cancer	9.49e-07	1.06e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—skin cancer	9.49e-07	1.06e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—skin cancer	9.49e-07	1.06e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—KRAS—skin cancer	9.47e-07	1.06e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—HRAS—skin cancer	9.42e-07	1.05e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—KRAS—skin cancer	9.42e-07	1.05e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NRAS—skin cancer	9.37e-07	1.05e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL6—skin cancer	9.36e-07	1.05e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HRAS—skin cancer	9.27e-07	1.04e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—NRAS—skin cancer	9.16e-07	1.03e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—KRAS—skin cancer	9.16e-07	1.03e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—skin cancer	9.15e-07	1.02e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ENO2—skin cancer	9.13e-07	1.02e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL6—skin cancer	9.08e-07	1.02e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—HRAS—skin cancer	9.07e-07	1.02e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—HRAS—skin cancer	9.07e-07	1.02e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HRAS—skin cancer	9.04e-07	1.01e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—BRAF—skin cancer	9.04e-07	1.01e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KRAS—skin cancer	9.03e-07	1.01e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL6—skin cancer	9.01e-07	1.01e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL6—skin cancer	8.87e-07	9.94e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KRAS—skin cancer	8.86e-07	9.92e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—HRAS—skin cancer	8.85e-07	9.92e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HRAS—skin cancer	8.81e-07	9.87e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—NRAS—skin cancer	8.78e-07	9.84e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—HRAS—skin cancer	8.75e-07	9.8e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—HRAS—skin cancer	8.72e-07	9.76e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—skin cancer	8.69e-07	9.73e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—skin cancer	8.69e-07	9.73e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HRAS—skin cancer	8.67e-07	9.71e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—skin cancer	8.66e-07	9.7e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ERCC2—skin cancer	8.61e-07	9.65e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KRAS—skin cancer	8.57e-07	9.6e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—HRAS—skin cancer	8.56e-07	9.58e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—KRAS—skin cancer	8.54e-07	9.56e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—skin cancer	8.48e-07	9.49e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—skin cancer	8.44e-07	9.45e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—skin cancer	8.37e-07	9.38e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—skin cancer	8.35e-07	9.35e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—skin cancer	8.34e-07	9.35e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—skin cancer	8.3e-07	9.3e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—skin cancer	8.24e-07	9.23e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NRAS—skin cancer	8.19e-07	9.17e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—skin cancer	8.19e-07	9.17e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—skin cancer	8.18e-07	9.16e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—skin cancer	8.14e-07	9.12e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—NRAS—skin cancer	8.11e-07	9.08e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—skin cancer	8.07e-07	9.04e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—skin cancer	8.05e-07	9.02e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—skin cancer	8.03e-07	8.99e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—skin cancer	8.01e-07	8.97e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NRAS—skin cancer	7.99e-07	8.95e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—skin cancer	7.99e-07	8.95e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—skin cancer	7.89e-07	8.84e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—skin cancer	7.88e-07	8.83e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NRAS—skin cancer	7.83e-07	8.77e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—skin cancer	7.79e-07	8.72e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NRAS—skin cancer	7.7e-07	8.63e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—skin cancer	7.7e-07	8.63e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—skin cancer	7.68e-07	8.6e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NRAS—skin cancer	7.66e-07	8.58e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—skin cancer	7.66e-07	8.58e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—skin cancer	7.61e-07	8.53e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—skin cancer	7.56e-07	8.47e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—skin cancer	7.53e-07	8.44e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—skin cancer	7.45e-07	8.35e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—skin cancer	7.35e-07	8.23e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—skin cancer	7.28e-07	8.16e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—skin cancer	7.26e-07	8.13e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—skin cancer	7.21e-07	8.07e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—skin cancer	7.17e-07	8.03e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—skin cancer	7.05e-07	7.9e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—skin cancer	6.98e-07	7.82e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—skin cancer	6.97e-07	7.81e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—skin cancer	6.95e-07	7.79e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—skin cancer	6.95e-07	7.78e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—skin cancer	6.88e-07	7.71e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—skin cancer	6.86e-07	7.68e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—skin cancer	6.74e-07	7.54e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—skin cancer	6.7e-07	7.51e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NRAS—skin cancer	6.66e-07	7.46e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—skin cancer	6.66e-07	7.45e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—skin cancer	6.63e-07	7.43e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—skin cancer	6.6e-07	7.39e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—skin cancer	6.56e-07	7.35e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—skin cancer	6.43e-07	7.2e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NRAS—skin cancer	6.41e-07	7.18e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—skin cancer	6.41e-07	7.18e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—skin cancer	6.27e-07	7.02e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—skin cancer	6.15e-07	6.89e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—skin cancer	6.11e-07	6.85e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—skin cancer	5.99e-07	6.71e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—skin cancer	5.99e-07	6.71e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—skin cancer	5.93e-07	6.64e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—skin cancer	5.89e-07	6.6e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—skin cancer	5.86e-07	6.57e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—skin cancer	5.85e-07	6.55e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—skin cancer	5.74e-07	6.42e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—skin cancer	5.73e-07	6.42e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—skin cancer	5.72e-07	6.41e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NRAS—skin cancer	5.68e-07	6.36e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—skin cancer	5.68e-07	6.36e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—skin cancer	5.64e-07	6.31e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—skin cancer	5.61e-07	6.28e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—skin cancer	5.6e-07	6.27e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—skin cancer	5.52e-07	6.18e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—skin cancer	5.48e-07	6.14e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—skin cancer	5.39e-07	6.04e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—skin cancer	5.37e-07	6.01e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ERCC2—skin cancer	5.31e-07	5.94e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—skin cancer	5.16e-07	5.78e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—skin cancer	5.09e-07	5.7e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—skin cancer	4.91e-07	5.5e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—skin cancer	4.89e-07	5.47e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—skin cancer	4.87e-07	5.45e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—skin cancer	4.69e-07	5.26e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—skin cancer	4.66e-07	5.22e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—skin cancer	4.49e-07	5.03e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—skin cancer	4.34e-07	4.87e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—skin cancer	4.15e-07	4.65e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—skin cancer	3.98e-07	4.45e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—skin cancer	3.18e-07	3.56e-06	CbGpPWpGaD
